DGI Focus —

DGI is focused on gene therapies for diseases of the blood, including Fanconi Anemia, Hemophilia A and AIDs. We are in the process of filing an Initial New Drug (IND) application as we prepare for clinical trials for Fanconi Anemia.

DGI SB-THERAPEUTICS PIPELINE
Current Focus (Orphan Diseases)	Disease	Gene	Market	DGI Advantages
	Fanconi Anemia (ready for clinical trials)	Fanc-C & Fanc-A	>$300 M	IND & Orphan Drug filing in progress; SBIR funding; patients available.
	Hemophilia A	Factor VIII	>$500 M	SBIR funding; DGI partners.

(Orphan Disease)	Brain Tumors	IL13-HSVTK	$2 B/yr	Founder's discovery
R & D	Cancer	EC2-peptide*	$4-5 B/yr	Patent filed.
	Ischemia	AN1, SRP1, AN2, EC1, EC2*	$10 B/yr	Patents filed.
	AIDS	siRNAs	>$10 B/yr
	* DGI Proprietary Patent Pending Biologicals

DGI Focus —

Current Focus

R & D